Larysa Sanchez, Ajai Chari, Mu Cheng, Dasha Cherepanov, Maral DerSarkissian, Fei Huang, Dawn Marie Stull, Jonathan Dabora, Melanie Young, Stephen J Noga, Selina Pi, Melody Zhang, Azeem Banatwala, Mei Sheng Duh, Sikander Ailawadhi
BACKGROUND: Economic differences among currently available proteasome inhibitors (PI)-based lenalidomide-dexamethasone (Rd)-backbone triplet regimens-ixazomib (I), bortezomib (V), and carfilzomib (K) plus Rd-remain poorly understood. OBJECTIVE: To assess health care resource utilization (HCRU) and health care costs of patients with relapsed/refractory multiple myeloma (RRMM) in the United States treated with IRd, VRd, and KRd. METHODS: This retrospective longitudinal cohort study using IQVIA PharMetrics Plus adjudicated claims US data (January 1, 2015, to September 30, 2020) included adult patients with all available data who initiated IRd, VRd, or KRd in second line of therapy or later (LOT2+) on or after September 1, 2015...
September 30, 2023: Journal of Managed Care & Specialty Pharmacy